ARTICLE REVIEW 2

Running head: ARTICLE REVIEW 1

Article Review

Name

Institutional Affiliations

Article Review

According to Bruneau, Ahamad, Goyer, Poulin, Selby, Fischer, Wild & Wood's (2018) review,
various hypotheses were formulated as recommendations for the treatment of opioid addiction in
Canada. The first hypothesis included the use of oral opioid agonist treatment and antagonist
pharmacotherapies. Psychosocial treatment interventions and withdrawal management strategies
were also recommended as possible treatment options. Bruneau eta l. (2018) also recommended
the use of residential treatment as a way of treating opioid addiction. The researchers found that
the use of opioid agonist treatment complemented with buprenorphine-naloxone would be the
best option for opioid treatment.

Opioid agonist treatment complemented with buprenorphine-naloxone and withdrawal

management was used as the main interventions in the review. The researchers found out that
opioid agonist treatment complemented with buprenorphine-naloxone was the main intervention
that can be used to treat opioid addiction in Canada. However, they also recommended the use of
withdrawal management strategies in the process of using the initial intervention. Bruneau et al.
(2018) insisted that it is not appropriate to implement withdrawal management strategies when
the patient is in isolation. According to them, this intervention could lead to other social
problems that would further complicate the recovery of the patient.

The principal participants in the research included individuals nominated from each node of the
Canadian Research Initiative in Substance Misuse (CRISM). The principal participants were
responsible for their respective regions. They also invited stakeholder participants within their
regions to take part in the review process. In total, the review committee consisted of 43
individuals. These members were selected randomly based on their willingness to be part of the
review committee and their standard of knowledge when it comes to healthcare and the issue of
opioid addiction. Some of the groups of individuals that were part of the review committee
included social workers, registered nurses, nurse practitioners, and addiction medicine
physicians. All these individuals had a special role to play based on their contributions to the
review of the guidelines.

Data collection in the research involved the compilation of the recommendations for the
guidelines. Data collection involved a consensus where all the members of the committee agreed
on the guidelines that would suit dealing with the opioid situation based on the professional skills
of the committee members. The analysis of the data collected was done through the Grading of
Recommendations Assessment. Seemingly, the Development and Evaluation (GRADE) tool was
also used in the analysis process. All members made the interpretation of data of the committee
in two rounds. These committee members provided their view of the recommendations and the
changes that could be made in order to increase efficiency. Guideline editors were also involved
in the editing of the guidelines in order to come up with the final set of data.

I believe the combination of opioid agonist treatment complemented with buprenorphine-

naloxone and withdrawal management strategies can use in any town when it comes to dealing
with the opioid problem. The opioid agonist treatment complemented with buprenorphine-
naloxone has been proven to be the best option of opioid treatment, meaning that it can work on
any individual who is dealing with the condition. On the other hand, the use of withdrawal
management strategies would help the individuals to cope with the challenges that are associated
with the use of the opioid agonist treatment. This depicts that a dedicated implementation of
these two interventions in the right way could work in any place.
Reference

Bruneau, J., Ahamad, K., Goyer, M. È., Poulin, G., Selby, P., Fischer, B., … CIHR Canadian
Research Initiative in Substance Misuse (2018). Management of opioid use disorders: a national
clinical practice guideline. CMAJ : Canadian Medical Association journal = journal de
l'Association medicale canadienne, 190(9), E247–E257. doi:10.1503/cmaj.170958